An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The new Institute for Cell Therapy Discovery and Innovation will utilize expertise to develop cell therapies for cancer, autoimmune diseases, and infections.

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & ...

Leads developed LBL-051 using its antibody platform, dubbed LeadBody. The antibody binds to CD3 on T cells and CD19 and BCMA ...

The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...

Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen ...

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing ...